BFAI

BFAI
Clinical data
Other names	5,6-Benzofuranyl-2-aminoindane; 5,6-Benzofuranyl-2-aminoindan
Drug class	Selective serotonin releasing agent; Entactogen
ATC code	None;
Identifiers
	IUPAC name 6,7-dihydro-5H-cyclopenta[f][1]benzofuran-6-amine;
CAS Number	2760617-90-9 ;
PubChem CID	162728212;
Chemical and physical data
Formula	C11H11NO
Molar mass	173.215 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C(CC2=C1C=C3C=COC3=C2)N;
	InChI InChI=1S/C11H11NO/c12-10-4-8-3-7-1-2-13-11(7)6-9(8)5-10/h1-3,6,10H,4-5,12H2; Key:SYCRQDBZPIEBIR-UHFFFAOYSA-N;

BFAI, also known as 5,6-benzofuranyl-2-aminoindane, is a drug of the 2-aminoindane family that acts as a serotonin releasing agent (SSRA) and may produce entactogenic effects in humans, which may be useful for psychotherapeutic applications. It is closely related to MDAI but with the benzodioxole ring system replaced by benzofuran.^[1] The drug was patented by Matthew Baggott and Tactogen in 2022.^[1]

References

^ ^a ^b WO 2022/032147, Baggott M, "2-Aminoindane compounds for mental disorders or enhancement.", published 10 February 2022, assigned to Tactogen Inc.